Definition/General

Introduction:
-Diabetic mastopathy is a benign fibroinflammatory lesion of the breast that occurs in patients with long-standing, insulin-dependent diabetes mellitus
-It is histologically identical to lymphocytic mastitis.
Origin:
-It is thought to be an autoimmune reaction, possibly related to the glycosylation of proteins in the diabetic state.
Classification: It is a form of lymphocytic mastitis.
Epidemiology:
-It is a rare condition, typically affecting premenopausal women with a long history of type 1 diabetes mellitus.

Clinical Features

Presentation:
-Presents as a painless, hard, palpable mass that can be bilateral and multicentric
-It can be clinically suspicious for malignancy.
Symptoms: A painless, hard breast lump is the most common symptom.
Risk Factors: Type 1 diabetes mellitus is the main risk factor.
Screening:
-Mammography shows a dense, ill-defined mass
-Ultrasound shows a hypoechoic, irregular mass with posterior acoustic shadowing.

Master Diabetic Mastopathy Pathology with RxDx

Access 100+ pathology videos and expert guidance with the RxDx app

Gross Description

Appearance:
-An ill-defined, extremely hard, white-gray mass.
Characteristics: The lesion is very firm and fibrous.
Size Location: Size is variable.
Multifocality: Can be multifocal and bilateral.

Microscopic Description

Histological Features:
-The key feature is a dense, perilobular and periductal lymphocytic infiltrate composed of mature B-cells
-There is also prominent keloidal-type fibrosis and atrophic lobules
-Epithelioid fibroblasts can be seen.
Cellular Characteristics:
-The infiltrate is composed of small, mature lymphocytes.
Architectural Patterns: A perilobular and periductal pattern of inflammation and fibrosis is characteristic.
Grading Criteria: This is a benign inflammatory process.

Immunohistochemistry

Positive Markers: The lymphocytes are predominantly B-cells (CD20 positive).
Negative Markers: Not typically required for diagnosis.
Diagnostic Utility: IHC can be used to confirm the B-cell nature of the infiltrate.
Molecular Subtypes: Molecular subtyping is not relevant for this benign condition.

Molecular/Genetic

Genetic Mutations: This is a benign condition and is not associated with specific genetic mutations.
Molecular Markers: No specific molecular markers are routinely used for diagnosis.
Prognostic Significance:
-This is a benign condition, but it can recur
-It is not associated with an increased risk of breast cancer.
Therapeutic Targets:
-Treatment is usually conservative
-Surgery may be performed to exclude malignancy.

Differential Diagnosis

Similar Entities:
-Invasive carcinoma
-Lymphoma.
Distinguishing Features:
-Invasive carcinoma has malignant epithelial cells
-Lymphoma has a monotonous infiltrate of atypical lymphoid cells.
Diagnostic Challenges:
-The main challenge is to distinguish it from invasive carcinoma due to the clinical and radiological findings
-The dense fibrosis can also make it difficult to interpret on core biopsy.
Rare Variants: There are no specific rare variants.

Sample Pathology Report

Template Format

Sample Pathology Report

Complete Report: This is an example of how the final pathology report should be structured for this condition.

Specimen Information

[specimen type], measuring [size] cm in greatest dimension

Diagnosis

[diagnosis name]

Classification

Classification: [classification system] [grade/type]

Histological Features

Shows [architectural pattern] with [nuclear features] and [mitotic activity]

Size and Extent

Size: [X] cm, extent: [local/regional/metastatic]

Margins

Margins are [involved/uninvolved] with closest margin [X] mm

Lymphovascular Invasion

Lymphovascular invasion: [present/absent]

Lymph Node Status

Lymph nodes: [X] positive out of [X] examined

Special Studies

IHC: [marker]: [result]

Molecular: [test]: [result]

[other study]: [result]

Final Diagnosis

Final diagnosis: [complete diagnosis]